Soy isoflavones supplementation for patients with irritable bowel syndrome: A randomized double blind clinical trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Soy isoflavones supplementation for patients with irritable bowel syndrome: A randomized double blind clinical trial. / Jalili, Mahsa; Vahedi, Homayoon; Janani, Leila; Poustchi, Hossein; Malekzadeh, Reza; Hekmatdoost, Azita.
I: Middle East Journal of Digestive Diseases, Bind 7, Nr. 3, 2015, s. 170-176.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Soy isoflavones supplementation for patients with irritable bowel syndrome: A randomized double blind clinical trial
AU - Jalili, Mahsa
AU - Vahedi, Homayoon
AU - Janani, Leila
AU - Poustchi, Hossein
AU - Malekzadeh, Reza
AU - Hekmatdoost, Azita
N1 - (Ekstern)
PY - 2015
Y1 - 2015
N2 - Background: Irritable bowel syndrome (IBS) is one of the common gastrointestinal disorders with unknown etiology. In experimental models, it is proposed that soy isoflavones may suppress the clinical and psychological symptoms of IBS by alteration of gut barrier tight junctions.Methods: We conducted this study to evaluate the effects of soy isoflavones on IBS symptoms and patients’ quality of life. In a randomized double blind placebo-controlled clinical trial, 67 patients with IBS were allocated to consume either soy isoflavones capsules or a placebo for 6 weeks. The primary outcome was a significant reduction in symptoms severity score and the secondary outcome was a significant improvement in quality of life.Results: 45 participants completed the study. There was no significant changes in mean differences of symptoms severity score between the two groups; however soy isoflavone supplementation could significantly improve the qualityof life scores (p=0.009).Conclusion: Soy isoflavones supplementation could improve the quality of life in patients with IBS; however it did not suppress the symptoms severity in 6 weeks. Further research with a longer duration is needed to determine the sustained clinical efficacy. This study was registered at clinicaltrials.gov as NCT02026518
AB - Background: Irritable bowel syndrome (IBS) is one of the common gastrointestinal disorders with unknown etiology. In experimental models, it is proposed that soy isoflavones may suppress the clinical and psychological symptoms of IBS by alteration of gut barrier tight junctions.Methods: We conducted this study to evaluate the effects of soy isoflavones on IBS symptoms and patients’ quality of life. In a randomized double blind placebo-controlled clinical trial, 67 patients with IBS were allocated to consume either soy isoflavones capsules or a placebo for 6 weeks. The primary outcome was a significant reduction in symptoms severity score and the secondary outcome was a significant improvement in quality of life.Results: 45 participants completed the study. There was no significant changes in mean differences of symptoms severity score between the two groups; however soy isoflavone supplementation could significantly improve the qualityof life scores (p=0.009).Conclusion: Soy isoflavones supplementation could improve the quality of life in patients with IBS; however it did not suppress the symptoms severity in 6 weeks. Further research with a longer duration is needed to determine the sustained clinical efficacy. This study was registered at clinicaltrials.gov as NCT02026518
KW - Faculty of Science
KW - Irritable Bowel Syndrome
KW - Randomized clinical trial
KW - Quality of life
KW - Soy isoflavone
M3 - Journal article
C2 - 26396720
VL - 7
SP - 170
EP - 176
JO - Middle East Journal of Digestive Diseases
JF - Middle East Journal of Digestive Diseases
SN - 2008-5230
IS - 3
ER -
ID: 272716708